Latest news newssearch boxGO All Ad hoc Other 04 Mar 2020 Janssen submits European Marketing Authorization Application for ponesimod for treatment of adults with relapsing multiple sclerosis 06 Feb 2020 Idorsia announces financial results for 2019 – clinical programs advanced markedly – approaching first key results 10 Jan 2020 Neurocrine Biosciences and Idorsia amend option agreement to license novel treatment for rare pediatric epilepsy 05 Dec 2019 Idorsia and Mochida enter into a license agreement for the supply, co-development and co-marketing of daridorexant in Japan 19 Nov 2019 Idorsia enters into a collaboration with Antares for the development of a novel self-administered drug-device product for selatogrel 11 Nov 2019 Encouraging Phase 2 data on cenerimod – Idorsia's S1P1 receptor modulator currently investigated for SLE – presented at ACR 2019 22 Oct 2019 Idorsia announces financial results for the first nine months of 2019 02 Oct 2019 Data on cenerimod – Idorsia's S1P1 receptor modulator – will be presented at the ACR / ARP Annual Meeting 2019 11 Sep 2019 Janssen reports new head-to-head Phase 3 study data show ponesimod superiority versus Aubagio (teriflunomide) 14 mg in adults with relapsing multiple sclerosis 03 Sep 2019 Phase 2 data of selatogrel, Idorsia’s highly-selective P2Y12 receptor antagonist, presented at ESC 2019 31 Aug 2019 Phase 2 data of aprocitentan, Idorsia’s dual endothelin receptor antagonist, presented at ESC 2019 23 Aug 2019 Clinical data on Idorsia's pipeline compounds will be presented at the European Society of Cardiology Congress 2019 26 Jul 2019 Janssen reports positive top-line Phase 3 results for ponesimod in adults with relapsing multiple sclerosis 23 Jul 2019 Idorsia announces financial results for the first half of 2019 13 Jun 2019 Efficacy and safety data with Idorsia's dual orexin receptor antagonist presented at SLEEP 2019 in San Antonio 03 May 2019 Idorsia holds its second Annual General Meeting of Shareholders - All Board proposals approved 18 Apr 2019 Idorsia announces financial results for the first quarter 2019 29 Mar 2019 Idorsia issues invitation to 2019 Annual General Meeting of Shareholders 07 Feb 2019 Idorsia announces financial results for 2018 - outstanding progress made - four late stage assets advanced into Phase 3 05 Feb 2019 Idorsia announces the first patient recruited into REACT - the Phase 3 registration study with clazosentan 1 2 3 4 5 6 7 8
